Last reviewed · How we verify
TAK-341
At a glance
| Generic name | TAK-341 |
|---|---|
| Also known as | MEDI1341 |
| Sponsor | Takeda |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of TAK-341 in Treatment of Multiple System Atrophy (PHASE2)
- Single Ascending Dose Study of MEDI1341 in Healthy Volunteers (PHASE1)
- Multiple Ascending Dose Study of MEDI1341 in Patients With Parkinson's Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TAK-341 CI brief — competitive landscape report
- TAK-341 updates RSS · CI watch RSS
- Takeda portfolio CI